Balyasny Asset Management L.P. Acquires Shares of 33,536 LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Balyasny Asset Management L.P. acquired a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 33,536 shares of the medical instruments supplier’s stock, valued at approximately $3,090,000.

Several other institutional investors have also recently bought and sold shares of LMAT. Raymond James Financial Inc. bought a new position in LeMaitre Vascular in the 4th quarter valued at $14,900,000. Rockefeller Capital Management L.P. bought a new stake in shares of LeMaitre Vascular during the fourth quarter worth $7,787,000. Segall Bryant & Hamill LLC bought a new stake in shares of LeMaitre Vascular during the fourth quarter worth $5,446,000. Invesco Ltd. raised its position in shares of LeMaitre Vascular by 50.5% during the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier’s stock worth $16,124,000 after acquiring an additional 58,720 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of LeMaitre Vascular by 45.9% during the fourth quarter. JPMorgan Chase & Co. now owns 147,489 shares of the medical instruments supplier’s stock worth $13,590,000 after acquiring an additional 46,430 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares of the company’s stock, valued at approximately $456,915.68. The trade was a 26.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Trading Down 1.6%

NASDAQ LMAT opened at $80.20 on Monday. The stock has a 50-day simple moving average of $84.15 and a 200 day simple moving average of $93.14. The company has a market capitalization of $1.81 billion, a PE ratio of 43.83, a P/E/G ratio of 2.22 and a beta of 0.86. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.02). The company had revenue of $59.87 million during the quarter, compared to the consensus estimate of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.44 EPS. As a group, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 29th. Investors of record on Thursday, May 15th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 1.00%. LeMaitre Vascular’s dividend payout ratio is presently 40.40%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Lake Street Capital boosted their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price for the company. Five analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $98.14.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.